Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms

When AstraZeneca inked its massive $39 billion Alexion buyout, the company sought to get its hands on new revenue sources and to bolster its presence in rare diseases. If Alexion's second-quarter sales are any indication, the company is picking up two healthy blockbuster franchises.